glp 1 and chronic pain Migraines being treated with GLP-1? Here's what's Happening Potential Use of GLP-1 and

Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease

Hyperuricemia is a globally prevalent condition, particularly in high- and middle-income countries

A 2025 study found that tripling semaglutides dose to 7.2 mg led to roughly 19% weight loss over 72 weeks, compared to 16% at the standard dose, a meaningful gain, though with higher rates of side effects

Lawsuits argue that drug manufacturers failed to adequately warn consumers and healthcare providers about the significant risks tied to these drugs

"I've spent over 30 years doing research and helping my patients successfully manage their weight using medication

, ,